Edouard Lansiaux, Pierre-Philippe Pébaÿ, Jean-Laurent Picard, Joachim Son-Forget
{"title":"Meta-analysis:新冠肺炎疾病严重程度与吸烟状况相关","authors":"Edouard Lansiaux, Pierre-Philippe Pébaÿ, Jean-Laurent Picard, Joachim Son-Forget","doi":"10.1097/CPM.0000000000000364","DOIUrl":null,"url":null,"abstract":"The novel Coronavirus Disease 2019 (COVID-19) disease is a contagious acute respiratory infectious disease whose causative agent has been demonstrated to be a new virus of the coronavirus family, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Multiple studies have already reported that risk factors for severe disease include older age and the presence of at least one of several underlying health conditions. However, a recent physiopathologic report and the French COVID-19 scientific council have postulated a protective effect of tobacco smoking. Thanks to a meta-analysis, we have been able to demonstrate the statistical significance in this regard of 12 series from China, France, and the United States, reporting 3 different smoking statuses (current smoker, former smoker with a smoking history) and disease severity [with odds ratio of 1.78 (1.08-3.10), 4.60 (3.13-7.17), 2.74 (0.63-5.89), respectively]. Subsequently, and using a Bayesian approach, we have established that past and present smoking is associated with more severe COVID-19 outcomes. Finally, we refute claims linking general population smoking status [N=O(108) or O(109)] to much smaller disease course series [N=O(104)]. The latter point, in particular, is presented to stimulate academic discussion, and must be further investigated by well-designed studies.","PeriodicalId":10393,"journal":{"name":"Clinical Pulmonary Medicine","volume":"27 1","pages":"104 - 99"},"PeriodicalIF":0.0000,"publicationDate":"2020-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/CPM.0000000000000364","citationCount":"1","resultStr":"{\"title\":\"Meta-analysis: COVID-19 Disease Severity Correlates With Smoking Status\",\"authors\":\"Edouard Lansiaux, Pierre-Philippe Pébaÿ, Jean-Laurent Picard, Joachim Son-Forget\",\"doi\":\"10.1097/CPM.0000000000000364\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The novel Coronavirus Disease 2019 (COVID-19) disease is a contagious acute respiratory infectious disease whose causative agent has been demonstrated to be a new virus of the coronavirus family, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Multiple studies have already reported that risk factors for severe disease include older age and the presence of at least one of several underlying health conditions. However, a recent physiopathologic report and the French COVID-19 scientific council have postulated a protective effect of tobacco smoking. Thanks to a meta-analysis, we have been able to demonstrate the statistical significance in this regard of 12 series from China, France, and the United States, reporting 3 different smoking statuses (current smoker, former smoker with a smoking history) and disease severity [with odds ratio of 1.78 (1.08-3.10), 4.60 (3.13-7.17), 2.74 (0.63-5.89), respectively]. Subsequently, and using a Bayesian approach, we have established that past and present smoking is associated with more severe COVID-19 outcomes. Finally, we refute claims linking general population smoking status [N=O(108) or O(109)] to much smaller disease course series [N=O(104)]. The latter point, in particular, is presented to stimulate academic discussion, and must be further investigated by well-designed studies.\",\"PeriodicalId\":10393,\"journal\":{\"name\":\"Clinical Pulmonary Medicine\",\"volume\":\"27 1\",\"pages\":\"104 - 99\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-04-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1097/CPM.0000000000000364\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Pulmonary Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/CPM.0000000000000364\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pulmonary Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/CPM.0000000000000364","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Meta-analysis: COVID-19 Disease Severity Correlates With Smoking Status
The novel Coronavirus Disease 2019 (COVID-19) disease is a contagious acute respiratory infectious disease whose causative agent has been demonstrated to be a new virus of the coronavirus family, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Multiple studies have already reported that risk factors for severe disease include older age and the presence of at least one of several underlying health conditions. However, a recent physiopathologic report and the French COVID-19 scientific council have postulated a protective effect of tobacco smoking. Thanks to a meta-analysis, we have been able to demonstrate the statistical significance in this regard of 12 series from China, France, and the United States, reporting 3 different smoking statuses (current smoker, former smoker with a smoking history) and disease severity [with odds ratio of 1.78 (1.08-3.10), 4.60 (3.13-7.17), 2.74 (0.63-5.89), respectively]. Subsequently, and using a Bayesian approach, we have established that past and present smoking is associated with more severe COVID-19 outcomes. Finally, we refute claims linking general population smoking status [N=O(108) or O(109)] to much smaller disease course series [N=O(104)]. The latter point, in particular, is presented to stimulate academic discussion, and must be further investigated by well-designed studies.
期刊介绍:
Clinical Pulmonary Medicine provides a forum for the discussion of important new knowledge in the field of pulmonary medicine that is of interest and relevance to the practitioner. This goal is achieved through mini-reviews on focused sub-specialty topics in areas covered within the journal. These areas include: Obstructive Airways Disease; Respiratory Infections; Interstitial, Inflammatory, and Occupational Diseases; Clinical Practice Management; Critical Care/Respiratory Care; Colleagues in Respiratory Medicine; and Topics in Respiratory Medicine.